In a recent study, hyperbilirubinemia in patients receiving an ATV-based regimen was significantly associated with UGT1A1 rs887829 T allele, higher baseline bilirubin levels and slower plasma ATV clearance [14]. This evidence concerns the gene UGT1A1 and Hyperbilirubinemia.